WALLKILL BIOPHARMA
WALLKILL BIOPHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2017-01-01
Address:
Wilmington, Delaware, United States
Country:
United States
Total Employee:
11+
Status:
Active
Contact:
858 900-1521
Total Funding:
207.51 K USD
Similar Organizations
Atlantis Prima Indonesia
PT Atlantis Prima Indonesia
Geneius
Geneius is a Biotechnology company.
Initiator Pharma
Initiator Pharma is a Biotech company
KBP Biosciences
A multinational clinical stage biotechnology company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Osteo-Pharma
Osteo-Pharma is a technology platform
Sivec Biotechnologies
SiVEC Biotechnologies is a bio technology company.
Spark Biopharma
Spark Biopharma is a biotechnology company
More informations about "Wallkill BioPharma"
Wallkill BioPharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 22, 2017: Pre Seed Round …See details»
EIN 82-3737885 - Wallkill Biopharma Inc., Wilmington, Delaware
The Employer Identification Number (EIN) for Wallkill Biopharma Inc. is 82-3737885. EIN numbers are also referred to as FEIN or FTIN. Find EIN, Contact Details for Wallkill Biopharma Inc.. ...See details»
Wallkill BioPharma - Crunchbase
Wallkill BioPharma is a Biotechnology Company. Start Free Trial . Chrome ExtensionSee details»
Wallkill BioPharma Inc. - fund raising filing
Mar 28, 2018 Wallkill BioPharma Inc. - Most recent fund raising on March 28, 2018 raised $207,513 in Equity. FormDs.com . Newest; Filter; Local; Wallkill BioPharma Inc. Industry: …See details»
WALLKILL BIOPHARMA INC Wilmington DE, 19805 - Company …
Free Business profile for WALLKILL BIOPHARMA INC at 1013 Centre Rd, Wilmington, DE, 19805-1270, US.See details»
WALLKILL BIOPHARMA INC. | California Companies Directory
WALLKILL BIOPHARMA INC. was registered on 20 Feb 2019 as Foreign Stock company type incorporated at 5805 SOUTHERN HILLS CT, FLOWER MOUND, TX 75022. The agent name …See details»
823737885 EIN/TAX ID | WALLKILL BIOPHARMA INC. - HIPAASpace
WALLKILL BIOPHARMA INC. Conformed submission company name, business name, organization name, etc CIK: 0001735845: Company's Central Index Key (CIK). The Central …See details»
Wallkill Biopharma, Inc.:Financial,Market Cap,Revenue & Financial ...
Discovery Company profile page for Wallkill Biopharma, Inc. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
WALLKILL BIOPHARMA INC. - HIPAASpace
WALLKILL BIOPHARMA INC. BUSINESS ADDRESS EIN 823737885 An Employer Identification Number (EIN) is also known as a Federal Tax Identification Number, and is used to identify a …See details»
Wallkill Biopharma Inc - VC DATALAB profile
Wallkill Biopharma Inc 1013 Centre Road Suite 403-b Wilmington, DE 19805 United States. Open map. Phone (858) 900-1521. Search trends. Patents. KANDO id: 7381982. Corporate …See details»
Wallkill BioPharma, Inc. - US Patent and Trademark Search
Wallkill BioPharma Inc. of DELAWARE uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and …See details»
Wallkill BioPharma, Inc. - Entity | RPX Insight
Wallkill BioPharma, Inc. has 0 patent litigation cases (0 cases currently active) - 0 patents asserted - 0 cases as a plaintiff - 0 cases as a defendantSee details»
Wallkill Biopharma Inc | AUM 13F
Wallkill Biopharma Inc; Firm: Fund # CIK # 0001735845: Sale: 2017-10-22 ($0.2 MM Offered, $0.2 MM Sold) Fund: Phone: 8589001521: Address: 1013 Centre Road Wilmington, Delaware …See details»
FDA to pharmaceutical companies: Certain studies conducted by …
19 hours ago FDA has identified significant data integrity and study conduct concerns with bioequivalence and bioavailability studies conducted by Raptim Research Pvt. Ltd., a contract …See details»
METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS - Wallkill …
What is claimed is: 1. 1-23. (canceled) 24. A method for reducing glucose levels in a medium comprising a hyperglycemic glucose concentration which method comprises: contacting said …See details»
Biopharma Trends: Focus on Innovation Amid Complexity | BCG
Jan 8, 2025 Novel treatments based on innovative science and new modalities are emerging faster than ever. Intensifying competition, payer pressures, and a steep patent cliff are testing …See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Vision 2028: How China could impact the global biopharma industry
1 Kiki Han, Franck Le Deu, Fangning Zhang, and Josie Zhou, “The dawn of China biopharma innovation,” McKinsey, October 29, 2021. Exhibit 1 Web <2022> <China biopharma> Exhibit …See details»
Reimagining the future of biopharma manufacturing - McKinsey
Oct 11, 2022 Lessons from other industries can inform the digital ambition around which they will align and mobilize the organization, draw up an execution road map, and forge capabilities to …See details»
Operational excellence in biopharma research and early …
Jan 9, 2025 In this article—which details the third ingredient (out of eight) for sustained R&D performance improvements introduced in our flagship article, “Making more medicines that …See details»